<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Telomir Pharmaceuticals, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock</link>
<description>Latest news and press releases for Telomir Pharmaceuticals, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/telomir-pharmaceuticals-inc-common-stock" rel="self" type="application/rss+xml" />
<item>
<title>Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)</title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-completes-acquisition-of-teli-pharmaceuticals-securing-global-rights-to-telomir-1-telomir-zn</link>
<guid isPermaLink="true">https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-completes-acquisition-of-teli-pharmaceuticals-securing-global-rights-to-telomir-1-telomir-zn</guid>
<pubDate>Fri, 24 Apr 2026 04:00:00 GMT</pubDate>
<description>Transaction establishes global ownership rights of lead program and includes initial capital funding with additional optional milestone-based capital support</description>
</item>
<item>
<title>Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman</title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telo-genomics-announces-appointment-of-john-farlinger-as-ceo-and-chairman-1</link>
<guid isPermaLink="true">https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telo-genomics-announces-appointment-of-john-farlinger-as-ceo-and-chairman-1</guid>
<pubDate>Tue, 31 Mar 2026 11:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - March 31, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, has appointed John Farlinger, currently chair of the Company's audit committee, as chief executive officer and chairman. In connection with Mr. Farlinger's appointment, the Company and Mr. Farlinger have entered into a...</description>
</item>
<item>
<title>Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models</title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-demonstrates-broad-tumor-cell-mortality-in-human-triple-negative-breast-cancer-models</link>
<guid isPermaLink="true">https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-demonstrates-broad-tumor-cell-mortality-in-human-triple-negative-breast-cancer-models</guid>
<pubDate>Tue, 17 Feb 2026 13:00:00 GMT</pubDate>
<description>Iron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cytotoxicity. MIAMI, FL / ACCESS Newswire / February 17, 2026 /Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage ...</description>
</item>
<item>
<title>Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging</title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-reports-data-supporting-130000880</link>
<guid isPermaLink="true">https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-reports-data-supporting-130000880</guid>
<pubDate>Thu, 05 Feb 2026 13:00:00 GMT</pubDate>
<description>Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic mechanisms. MIAMI, FLORIDA / ACCESS Newswire ...</description>
</item>
<item>
<title>Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models</title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-announces-telomir-1-130000878</link>
<guid isPermaLink="true">https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-announces-telomir-1-130000878</guid>
<pubDate>Mon, 05 Jan 2026 13:00:00 GMT</pubDate>
<description>In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread. MIAMI, FLORIDA / ACCESS Newswire / January 5, 2026 / Telomir Pharmaceuticals ...</description>
</item>
<item>
<title>Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development</title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-reports-favorable-ind-123000548</link>
<guid isPermaLink="true">https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-reports-favorable-ind-123000548</guid>
<pubDate>Thu, 18 Dec 2025 12:30:00 GMT</pubDate>
<description>No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL / ACCESS Newswire / December 18, 2025 /Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" ...</description>
</item>
<item>
<title>Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells</title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-reports-data-showing-130000419</link>
<guid isPermaLink="true">https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-reports-data-showing-130000419</guid>
<pubDate>Tue, 25 Nov 2025 13:00:00 GMT</pubDate>
<description>PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November 25, 2025 /Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ...</description>
</item>
<item>
<title>Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells</title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-announces-telomir-1-123000515</link>
<guid isPermaLink="true">https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-announces-telomir-1-123000515</guid>
<pubDate>Fri, 21 Nov 2025 12:30:00 GMT</pubDate>
<description>Findings expand Telomir-1's oncology profile into cancers of the blood, adding to previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. MIAMI, FL / ACCESS Newswire / November 21, 2025 / Telomir ...</description>
</item>
<item>
<title>Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line</title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-reports-telomir-1-130000614</link>
<guid isPermaLink="true">https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-reports-telomir-1-130000614</guid>
<pubDate>Wed, 12 Nov 2025 13:00:00 GMT</pubDate>
<description>New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent cell penetration and iron-modulating activity - key to its broader epigenetic mechanism ...</description>
</item>
<item>
<title>Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo</title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-reports-data-showing-113000475</link>
<guid isPermaLink="true">https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-reports-data-showing-113000475</guid>
<pubDate>Thu, 23 Oct 2025 11:30:00 GMT</pubDate>
<description>New findings highlight Telomir-1's impact on CASP8 and GSTP1, two critical genes that regulate cell death and glutathione-based detoxification pathways often disrupted in cancer. MIAMI, FLORIDA / ACCESS Newswire / October 23, 2025 / Telomir Pharmaceuticals, ...</description>
</item>
<item>
<title>Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth</title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-executes-binding-loi-113000654</link>
<guid isPermaLink="true">https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-executes-binding-loi-113000654</guid>
<pubDate>Tue, 21 Oct 2025 11:30:00 GMT</pubDate>
<description>Unifying global IP rights and enabling up to $5 million in potential shareholder contributions, the agreement strengthens Telomir's foundation for partnerships, licensing, and long-term value creation. MIAMI, FLORIDA / ACCESS Newswire / October 21, ...</description>
</item>
<item>
<title>Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer</title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-announces-data-showing-120000076</link>
<guid isPermaLink="true">https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-announces-data-showing-120000076</guid>
<pubDate>Tue, 14 Oct 2025 12:00:00 GMT</pubDate>
<description>Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1's consistent impact on cancer cell survival pathways. MIAMI, FLORIDA / ACCESS Newswire / October 14, 2025 /Telomir ...</description>
</item>
<item>
<title>Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells</title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-reports-discovery-telomir-113000231</link>
<guid isPermaLink="true">https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-reports-discovery-telomir-113000231</guid>
<pubDate>Thu, 09 Oct 2025 11:30:00 GMT</pubDate>
<description>New findings show Telomir-1 shuts down cellular energy pathways and mitochondrial function in aggressive breast cancer cells, leading to cell death through iron-dependent regulation. MIAMI, FL / ACCESS Newswire / October 9, 2025 /Telomir Pharmaceuticals, ...</description>
</item>
<item>
<title>Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance</title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-announces-findings-prostate-113000396</link>
<guid isPermaLink="true">https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-announces-findings-prostate-113000396</guid>
<pubDate>Tue, 07 Oct 2025 11:30:00 GMT</pubDate>
<description>Findings show that Telomir-1 restores the body's natural tumor suppressor defenses by reversing abnormal DNA methylation of MASPIN and RASSF1A - genes that help block invasion, limit metastasis, and improve chemotherapy responsiveness in aggressive ...</description>
</item>
<item>
<title>Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance </title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-announces-new-findings-in-a-prostate-cancer-model-demonstrating-telomir-1-also-resets-dna-methylation-of-tumor-suppressor-genes-implicated-in-two-of-the-most-persistent-challenges-in-oncology-metastasis-and-treatment-resistance</link>
<guid isPermaLink="true">https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-announces-new-findings-in-a-prostate-cancer-model-demonstrating-telomir-1-also-resets-dna-methylation-of-tumor-suppressor-genes-implicated-in-two-of-the-most-persistent-challenges-in-oncology-metastasis-and-treatment-resistance</guid>
<pubDate>Tue, 07 Oct 2025 04:00:00 GMT</pubDate>
<description>Findings show that Telomir-1 restores the body's natural tumor suppressor defenses by reversing abnormal DNA methylation of MASPIN and RASSF1A - genes that</description>
</item>
<item>
<title>Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies</title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-announces-vitro-data-120000251</link>
<guid isPermaLink="true">https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-announces-vitro-data-120000251</guid>
<pubDate>Thu, 18 Sep 2025 12:00:00 GMT</pubDate>
<description>New in vitro results show Telomir-1 adds KDM5 family inhibition to its previously reported KDM2/KDM6 and DNA methylation activity, potentially representing a novel frontier in epigenetic therapy where no existing candidates have shown comparable breadth. ...</description>
</item>
<item>
<title>Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy</title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-announces-cancer-data-120000308</link>
<guid isPermaLink="true">https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-announces-cancer-data-120000308</guid>
<pubDate>Tue, 09 Sep 2025 12:00:00 GMT</pubDate>
<description>New preclinical findings highlight Telomir-1's ability to reverse CDKN2A gene silencing by DNA methylation, reactivating this gene - often called the body's natural "cell cycle brake." These results build on prior STAT1 data, supporting Telomir-1's ...</description>
</item>
<item>
<title>Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases</title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-reports-vitro-data-120000051</link>
<guid isPermaLink="true">https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-reports-vitro-data-120000051</guid>
<pubDate>Thu, 28 Aug 2025 12:00:00 GMT</pubDate>
<description>In vitro findings reveal Telomir-1's dual action: targeting DNA methylation switches and cutting into the Wnt "fuel line" that drives cancer growth. MIAMI, FLORIDA / ACCESS Newswire / August 28, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), ...</description>
</item>
<item>
<title>Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction</title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-announces-vitro-data-120000963</link>
<guid isPermaLink="true">https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-announces-vitro-data-120000963</guid>
<pubDate>Thu, 07 Aug 2025 12:00:00 GMT</pubDate>
<description>New data from Eurofins Discovery show that Telomir-1 blocks enzymes that drive disease by turning off critical genes-highlighting its potential to treat cancer, autoimmune conditions, neurodegeneration, and metabolic disorders through epigenetic modulation. ...</description>
</item>
<item>
<title>Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson's</title>
<link>https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-reports-telomir-1s-120000423</link>
<guid isPermaLink="true">https://6ix.com/company/telomir-pharmaceuticals-inc-common-stock/news/telomir-pharmaceuticals-reports-telomir-1s-120000423</guid>
<pubDate>Thu, 24 Jul 2025 12:00:00 GMT</pubDate>
<description>This unique cellular activity may help restore energy balance and improve essential cell functions such as protein synthesis and membrane stability in diseases like Parkinson's ALS Alzheimer's and Progeria where mitochondrial failure and oxidative ...</description>
</item>
</channel>
</rss>